Journals / MN Kardiyoloji / 2006 / Cilt: 13 - Sayı: 3

Coxistence of primer antiphospholipid syndrome, factor V Leiden mutation and activated protein C resistance: A case report

Aktive protein C resistansı, faktör V Leiden mutasyonu ve primer antifosfolipid sendromunun bir arada bulunduğu bir olgu

Pages
220–223
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

This case illustrates importance of thrombofilias and some differences of long term managements in evaluation of young patients who present with venous thrombosis.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:t is known inherited and acquired thrombophilias are associated with thromboembolic events.
📊
Key Findings & Data:In this case report, a case with activated protein C resistance, Factor V Leiden mutation and lupus anticoagulant scrutinized.
💡
Conclusion & Impact:This case illustrates importance of thrombofilias and some differences of long term managements in evaluation of young patients who present with venous thrombosis.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Aktive protein C direnci · Lupus pıhtılaşma inhibitörü · Antifosfolipid sendromu

Abstract

t is known inherited and acquired thrombophilias are associated with thromboembolic events. In this case report, a case with activated protein C resistance, Factor V Leiden mutation and lupus anticoagulant scrutinized. This case illustrates importance of thrombofilias and some differences of long term managements in evaluation of young patients who present with venous thrombosis.

Özet

Akkiz ve kalıtılmış trombofililerin tromboembolik olaylarla ilişkili olduğu bilinmektedir. Bu olgu sunumunda aktive protein C resistansı, faktör V Leiden mutasyonu ve lupus antikoagülanının birlikte bulunduğu bir vaka gözden geçirildi. Bu olgu, venöz trombozla presente olmuş genç hastaların değerlendirilmesinde trombofili nedenlerinin önemine ve uzun dönem yönetimlerindeki bazı farklılıklara örnek teşkil etmektedir.

🔖

Cite This Article

ULUÇAY, A., TATLI, E., BÜYÜKLÜ, M. (2006). Coxistence of primer antiphospholipid syndrome, factor V Leiden mutation and activated protein C resistance: A case report. MN Kardiyoloji, Cilt: 13 - Sayı: 3, 220–223. https://ajindex.com/articles/297515

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Caprini JA, Glase CJ, Anderson CB, Hathaway K. Laboratory Mar-kers in the Diagnosis of Venous Thromboembolism. Cir-cu-la-tion 2004; 109:4-8.
  2. Lopez FF, Sweeney JD, Blair AJ, Sikov WM. Spontaneous ve-nous thrombosis in a young patient with combined factor V Lei-den and lupus anticoagulant. Am J Hematol 1999; 62:58-60.
  3. Busowski JD, Jenkins AD, Hale EU, Busowski M, Dacus JV.Acti-vated protein C resistance and lupus anticoagulant in preg­nancy. J Matem Fetal Med 1999; 8:298-9.
  4. Chopra N, Koren S, Greer WL, et al. Factor V Leiden, prothrom-bin gene mutation, and thrombosis risk in patients with antiphospholipid antibodies.J Rheumatol 2002; 29:1683-8.
  5. Kassis J, Neville C, Rauch J, et al. Antiphospholipid antibodi­ es and thrombosis: association with acquired activated protein C resistance in venous thrombosis and with hyperhomocysteinemia in arterial thrombosis. Thromb Haemost 2004; 92:1213-9. Dahlback B. New molecular insights into the genetics of thrombophilia: resistance to activated protein C caused by Arg506 to Gln mutation in factor V as a pathogenic risk factor for venous thrombosis. Thromb Haemost 1995; 74:139-148. Gardner J. Factor V Leiden with deep venous thrombosis.Clin Lab Sci 2003; 16:6-9.
  6. Dizon-Townson D, Miller C, Sibai B, et al. The relationship of the factor V Leiden mutation and pregnancy outcomes for mother and fetus. Obstet Gynecol 2005; 106:517-24.
  7. Ridker PM, Miletich JP, Stampfer MJ, et al. Factor V Leiden and risks of recurrent idipathic veonous thromboembolism. Circulation 1995; 92:2800-2.
  8. Eichinger S, Weltermann A, Mannhalter C, et al. Thes risk of recurrent venous thromboembolism in heterozygous carriers of factor V Leiden and a first spontaneous venous thromboembolism. Arch Intern Med 2002; 162:2357-60.
  9. De Stephano V, Martinelli I, Mannucci PM, et al. The risk of deep venous thrombosis among heterozygous carriers of both Factor V Leiden and G20210A prothrombin mutation. N Eng J Med 1999; 341:801-6.
  10. Wilson WA, Gharavi AE, Koike T, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop.Arthritis Rheum 1999; 42:1309-11.
  11. Levine JS, Branch DW, Rauch J. The antiphospholipid syndrome. N Engl J Med 2002; 346:752-63. Hanly JG. Antiphospholipid syndrome: an overview. CMAJ 2003; 168:1675-82.
  12. Aznar J, Villa P, Espana F, Estelles A, Grancha S, Falo C.Activated protein C resistance phenotype in patients with antiphospholipid antibodies. J Lab Clin Med